Vorsetuzumab

Research use only, not for human use.

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen.

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma.

Vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells in vitro.Vorsetuzumab (10 μg/mL; 2 h) can be developed into bispecific anti-human CD70/KWAR23 antibody, results KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1).

Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt’s lymphoma cell growth growth in SRG mice.Animal Model:Burkitt’s lymphoma xenograft model in SRG mice Dosage:10 mg/kg Administration: Intraperitoneal injection; every other day; for 12 d Result:Effectively inhibited Burkitt’s lymphoma cell growth but was not outperform the combination of the KWAR23 antibody (10 mg/kg).

——

Others

Other Targets

Immunology/Inflammation related

——

——

1165740-62-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years